Education
About Us
Working with TipRanks
Follow Us
Regulus (RGLS)
NASDAQ:RGLS
RGLS Stock Chart & Stats
Day’s Range― - ―
52-Week Range$0.83 - $2.90
Previous CloseN/A
Volume87.19K
Average Volume (3M)1.62M
Market Cap
$119.24M
Enterprise Value$16.66M
Total Cash (Recent Filing)$40.55M
Total Debt (Recent Filing)$10.13M
Price to Earnings (P/E)―
Beta1.03
Next Earnings
May 08, 2025EPS Estimate
-0.25Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.88
Shares Outstanding66,243,385
10 Day Avg. Volume4,294,427
30 Day Avg. Volume1,623,194
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
Price to Cash Flow (P/CF)-1.90
P/FCF Ratio0.00
Enterprise Value/Market Cap0.14
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/Ebitda-0.36
Forecast
1Y Price Target
$12.75Price Target Upside658.93% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering5
---
Regulus News
See All RGLS News
---
Bulls Say, Bears Say
Bulls Say
Clinical TrialsThe impressive results in early clinical trials of farabursen indicate a promising future if further trials confirm these findings.
FDA AlignmentThe accelerated approval pathway is in alignment with the FDA, which has agreed to the key components of the Phase 3 trial design.
Market PotentialFarabursen's potential to be prescribed to a larger proportion of patients compared to tolvaptan suggests strong market acceptance if clinical benefits are confirmed.
Bears Say
Efficacy UncertaintyThe observed efficacy on reducing htTKV growth rate at three months could be further strengthened at 12 months, supporting potential accelerated approval.
Financial ConcernsCash remains a question with the company ending the fourth quarter of 2024 with $75.8M in cash, with runway into early 2026.
---
Ownership Overview
2.79% Insiders
10.24% Mutual Funds
28.92% Other Institutional Investors
48.47% Public Companies and
Individual Investors
Risk Analysis
Main Risk Category
Finance & CorporateFinancial and accounting risks. Risks related to the execution of corporate activity and strategy
RGLS FAQ
What was Regulus’s price range in the past 12 months?
Regulus lowest stock price was $0.83 and its highest was $2.90 in the past 12 months.
What is Regulus’s market cap?
Regulus’s market cap is $119.24M.
When is Regulus’s upcoming earnings report date?
Regulus’s upcoming earnings report date is May 08, 2025 which is in 32 days.
How were Regulus’s earnings last quarter?
Regulus released its earnings results on Mar 13, 2025. The company reported -$0.2 earnings per share for the quarter, beating the consensus estimate of -$0.21 by $0.01.
Is Regulus overvalued?
According to Wall Street analysts Regulus’s price is currently Undervalued.
Does Regulus pay dividends?
Regulus does not currently pay dividends.
What is Regulus’s EPS estimate?
Regulus’s EPS estimate is -0.25.
How many shares outstanding does Regulus have?
Regulus has 66,243,385 shares outstanding.
What happened to Regulus’s price movement after its last earnings report?
Regulus reported an EPS of -$0.2 in its last earnings report, beating expectations of -$0.21. Following the earnings report the stock price went up 7.246%.
Which hedge fund is a major shareholder of Regulus?
Currently, no hedge funds are holding shares in RGLS
---
Regulus Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$12.75 (658.93% Upside)
$12.75 (658.93% Upside)
Blogger Sentiment
Bullish
RGLS Sentiment 100%
Sector Average 69%
Sector Average 69%
Hedge Fund Trend
Decreased
By 1.4M Shares
Last Quarter.
Last Quarter.
Insider Transactions
Bought Shares
Worth $74.8K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Negative
Last 7 Days ▼ 1.4%
Last 30 Days ▼ 4.9%
Last 30 Days ▼ 4.9%
News Sentiment
Neutral
Bullish news 50%
Bearish news 100%
Bearish news 100%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-33.13%
12-Months-Change
Fundamentals
Return on Equity
-95.00%
Trailing 12-Months
Asset Growth
173.76%
Trailing 12-Months
Company Description
Regulus
Regulus Therapeutics Inc., a clinical stage biopharmaceutical company, engages in the discovery and development of drugs that targets microRNAs to treat a range of diseases in the United States. Its product candidates include RG-012, an anti-miR targeting miR-21 that is in Phase II clinical trial for the treatment of Alport syndrome, a life-threatening kidney disease; and RGLS8429, an anti-miR targeting miR-17, which is in Phase 1b clinical study for the treatment of autosomal dominant polycystic kidney disease. The company is also developing a pipeline of preclinical drug products for target organ-selective delivery strategies. Regulus Therapeutics Inc. was incorporated in 2007 and is headquartered in San Diego, California.
---
RGLS Stock 12 Month Forecast
Average Price Target
$12.75
▲(658.93% Upside)
Technical Analysis
Alnylam Pharma
―
Arrowhead Pharmaceuticals
―
Ionis Pharmaceuticals
―
Sarepta Therapeutics
―
Moderna
―
Best Analysts Covering RGLS
1 Year
1 Year Success Rate
9/13 ratings generated profit
1 Year Average Return
+4.99%
reiterated a buy rating 23 days ago
Copying Ram Selvaraju's trades and holding each position for 1 Year would result in 69.23% of your transactions generating a profit, with an average return of +4.99% per trade.
---